Dominique Stump
A Helius Medical Technologies division will continue to test and develop its chronic balance deficit treatment under the extended sole-source contract from the U.S. Army Medical Research and Materiel Command.
NeuroHabilitation Corp. will conduct clinical trials across additional study sites through the end of this year in an effort to validate the safety and reliability of the Portable Neuromodulation Stimulator, the company said Monday.
“Extending this contract reflects a continued commitment from the USAMRMC, and Helius, to address the large unmet clinical need represented by both civilian and military patients that suffer chronic symptoms of traumatic brain injury,” said Phil Deschamps, Helius CEO.
PoNS works to remedy the chronic balance deficits of patients afflicted with mild to moderate traumatic injuries.
